Focus: Sanofi is a global Big Pharma company with 91,000 employees headquartered in Paris, France, operating across small molecules, biologics, immunology, oncology, vaccines, and rare diseases.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Sanofi to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sanofi's largest revenue driver, but facing biosimilar erosion and approaching loss of exclusivity; represents ~47% of company revenue.
Help build intelligence for Sanofi
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sanofi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary insulin franchise in decline due to LOE timeline and biosimilar competition.
Higher-concentration insulin formulation at peak sales; provides some portfolio diversification within diabetes space.
Blockbuster immunology/inflammation asset with multiple Phase 3 and Phase 4 programs; critical growth driver as insulin portfolio declines.
Established cardiovascular asset with patent exclusivity through 2031; solid mid-tier revenue contributor.
Mature MS therapeutic with extended LOE window; supports neurology franchise diversification.
224 discontinued, 26 duplicate formulations not shown
+16 more products with revenue data
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody-antigen interactions.
Dupilumab subgroup responder analysis: a post hoc analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis.
+20 more products
+2 more
+2 more
+2 more
+1 more
+2 more
+2 more
+2 more
+1 more
+2 more
No recent regulatory warnings or warn layoff filings detected; 2 active drug shortages (rifapentine, rifampin) do not suggest systemic manufacturing crisis—baseline risk profile favorable.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo